About: Identification of Novel Natural Products as Effective and Broad-Spectrum Anti-Zika Virus Inhibitors

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Identification of Novel Natural Products as Effective and Broad-Spectrum Anti-Zika Virus Inhibitors Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Identification of Novel Natural Products as Effective and Broad-Spectrum Anti-Zika Virus Inhibitors
Creator	Du, Lanying Jiang, Shibo Wang, Ning Tai, Wanbo Li, Xiang Gao, Yaning Chen, Shizhong Debnath, Asim
source	PMC
abstract	Zika virus (ZIKV) infection during pregnancy leads to severe congenital Zika syndrome, which includes microcephaly and other neurological malformations. No therapeutic agents have, so far, been approved for the treatment of ZIKV infection in humans; as such, there is a need for a continuous effort to develop effective and safe antiviral drugs to treat ZIKV-caused diseases. After screening a natural product library, we have herein identified four natural products with anti-ZIKV activity in Vero E6 cells, including gossypol, curcumin, digitonin, and conessine. Except for curcumin, the other three natural products have not been reported before to have anti-ZIKV activity. Among them, gossypol exhibited the strongest inhibitory activity against almost all 10 ZIKV strains tested, including six recent epidemic human strains. The mechanistic study indicated that gossypol could neutralize ZIKV infection by targeting the envelope protein domain III (EDIII) of ZIKV. In contrast, the other natural products inhibited ZIKV infection by targeting the host cell or cell-associated entry and replication stages of ZIKV. A combination of gossypol with any of the three natural products identified in this study, as well as with bortezomib, a previously reported anti-ZIKV compound, exhibited significant combinatorial inhibitory effects against three ZIKV human strains tested. Importantly, gossypol also demonstrated marked potency against all four serotypes of dengue virus (DENV) human strains in vitro. Taken together, this study indicates the potential for further development of these natural products, particularly gossypol, as the lead compound or broad-spectrum inhibitors against ZIKV and other flaviviruses, such as DENV.
has issue date	2019-11-02(xsd:dateTime)
bibo:doi	10.3390/v11111019
bibo:pmid	31684080
has license	cc-by
sha1sum (hex)	7d8b8767e12fc4fee2b29c6473b7dd1f3244b933
schema:url	https://doi.org/10.3390/v11111019
resource representing a document's title	Identification of Novel Natural Products as Effective and Broad-Spectrum Anti-Zika Virus Inhibitors
has PubMed Central identifier	PMC6893700
has PubMed identifier	31684080
schema:publication	Viruses
resource representing a document's body	covid:7d8b8767e12fc4fee2b29c6473b7dd1f3244b933#body_text
is schema:about of	named entity 'development' named entity 'human' named entity 'natural product' named entity 'treat' named entity 'diseases' named entity 'targeting' named entity 'NOVEL' covid:arg/7d8b8767e12fc4fee2b29c6473b7dd1f3244b933 named entity 'ZIKA VIRUS' named entity 'INHIBITORY' named entity 'CELLS' named entity 'RECENT' named entity 'NEED FOR' named entity 'INCLUDES' named entity 'SIGNIFICANT' named entity 'APPROVED' named entity 'MECHANISTIC STUDY' named entity 'EPIDEMIC' named entity 'COMPOUND' named entity 'BORTEZOMIB' named entity 'MICROCEPHALY' named entity 'TAKEN' named entity 'STUDY' named entity 'DEVELOPMENT' named entity 'HAVE' named entity 'LEADS' named entity 'THESE' named entity 'NATURAL PRODUCT' named entity 'ZIKA VIRUS' named entity 'HOST CELL' named entity 'DURING PREGNANCY' named entity 'IDENTIFIED' named entity 'CONTRAST' named entity 'REPLICATION' named entity 'CAUSED' named entity 'FETAL DEATH' named entity 'PREVIOUSLY' named entity 'REPORTED' named entity 'DISEASES' named entity 'ENTRY' named entity 'CONTINUOUS' named entity 'DIGITONIN' named entity 'TARGETING' named entity 'EFFORT' named entity 'BROAD' named entity 'VIRUS INHIBITORS' named entity 'EXCEPT FOR' named entity 'TESTED' named entity 'THERAPEUTIC AGENTS' named entity 'CONGENITAL ZIKA SYNDROME' named entity 'ASSOCIATED' named entity 'INFECTION' named entity 'SEVERE' named entity 'STAGES' named entity 'TREATMENT' named entity 'POTENTIAL' named entity 'INHIBITED' named entity 'MARKED' named entity 'BROAD' named entity 'INHIBITORY ACTIVITY' named entity 'VERO' named entity 'STRAINS' named entity 'SEROTYPES' named entity 'IDENTIFICATION' named entity 'NATURAL PRODUCTS' named entity 'SPECTRUM' named entity 'EFFECTIVE' named entity 'ENVELOPE PROTEIN DOMAIN III' named entity 'LIBRARY' named entity 'TREAT' named entity 'HUMAN' named entity 'POTENCY' named entity 'COMBINATION' named entity 'LEAD COMPOUND'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software